This site is intended for healthcare professionals

CPD
CPD
Pro
Pro
Sign in
Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Thioridazine

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Piperadine compounds produce less extrapyramidal side effects than other phenothiazines and so often used in elderly patients.

They may produce pigmentation of the retina in some patients and should not be given in large doses for long periods.

The CSM has advised that the use of thioridazine should be restricted to the second line treatment of schizophrenia in adults (1):

  • this advice follows consideration of the rare but serious cardiotoxicity (QTc interval prolongation and life-threatening ventricular arrhythmias) associated with the treatment with thioridazine.
  • it has been advised that thioridazine treatment should be supervised by a consultant psychiatrist

The summary of product characteristics should be consulted before prescribing this drug.

Reference:

  • (1) Message from Professor Alasdair Breckenridge, Chairman, Committee on Safety of Medicines, Thioridazine: restricted indications and new warnings on cardiotoxicity, 11/12/00.

Related pages

Create an account to add page annotations

Create a free account

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.